CTRI/2016/06/006991进行中（未招募）4 期
A drug utilization review of Galvus (vildagliptin) and GalvusMet (vildagliptin plus metformin fixed-drug combination) in type 2 diabetes mellitus - DUR
ovartis Healthcare Private Limited0 个研究点目标入组 800 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Adult (>= 18 years) T2DM patients of both genders, who have been prescribed vildagliptin or vildagliptin-metformin fixed-dose combination (Galvus or GalvusMet).
- •2.Written informed consent will be obtained from patients for use of their data in hospital database for the purpose of research
排除标准
- •Not applicable
研究者
相似试验
尚未招募
4 期
The efficacy and tolerability of Galvus (Vildagliptin) compared to Sulfonylureas in patients with new onset diabetes after transplantation (NODAT)ew onset diabetes after transplantRenal TransplantNew onset diabetes after transplantMetabolic and Endocrine - DiabetesRenal and Urogenital - Kidney diseaseACTRN12613000224729Sydney Local Health District48
已完成
不适用
Efficacy and Safety of Vildagliptin in Type 2 DiabetesCTRI/2022/01/039112Cipla Limited1,691
未知
1 期
To Assess the Efficacy and Safety of Vildagliptin in Patients with Type 2 DiabetesType 2 DiabetesJPRN-jRCT2080220150ovartis Pharma K.K.264
未知
3 期
To assess the efficacy and safety of vildagliptin as add-on therapy to sulfonylurea in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapyType 2 DiabetesJPRN-jRCT2080220244ovartis Pharma K.K.200
招募中
4 期
An study to assess the safety and efficacy of vildagliptin vs voglibose in management of post-prandial blood sugar in patients with T2DMCTRI/2024/08/072355Dr Mahima V